A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab combination followed by bevacizumab alone in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2010
At a glance
- Drugs Bevacizumab; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Dec 2008 Checked against ClinicalTrials.gov record.
- 03 Oct 2007 Status change from recruiting to discontinued.
- 08 Oct 2006 New trial record.